Good news! What a relief to so many! Unfortunately, the number of participants in this study was very low. A very interesting approach for treatment!
"86% of type 2 diabetes patients treated with a new procedure no longer needed insulin throughout the two-year-long study they participated in. That procedure could be a real game changer for nearly half a billion people currently estimated to be living with the condition worldwide. ...
It was conducted with a small group of 14 participants aged between 28 and 75 years, who were monitored over the course of 24 months. ...
It was conducted with a small group of 14 participants aged between 28 and 75 years, who were monitored over the course of 24 months. ...
In this new study ... carried out a procedure called Recellularization via Electroporation Therapy, or ReCET.
Electroporation is an endoscopic operation that applies controlled electric pulses to "create small, irreversible holes in the cell membranes," and is typically used to facilitate DNA delivery into cells. Here, it's being used to improve the body’s sensitivity to its own insulin. ...
At the 6- and 12-month follow-ups, 12 out of 14 participants no longer required insulin therapy. They didn't need it at the 24-month mark either. ...
"Unlike drug therapy, which requires daily medication adherence, ReCET is compliance-free, addressing the critical issue of ongoing patient adherence in the management of type 2 diabetes," she continued. "In addition, the treatment is disease-modifying: it improves the patient's sensitivity to their own (endogenous) insulin, tackling the root cause of the disease, as opposed to currently available drug therapies, that are at best disease-controlling." ..."
From the abstract:
"Background and Aims
Studies have shown that hydrothermal duodenal mucosal ablation results in improved glycemic control. Recellularization via electroporation therapy (ReCET) is a novel endoscopic procedure that uses electroporation to induce cellular apoptosis and subsequent reepithelization. In this study, we aimed to eliminate exogenous insulin treatment in type 2 diabetes (T2D) patients through a single ReCET procedure combined with a glucagon-like peptide 1 receptor agonist. Feasibility, safety, and (dose) efficacy of ReCET were assessed.
Methods
This first-in-human study included patients with T2D on basal insulin (age, 28-75 years; body mass index, 24-40 kg/m2; glycosylated hemoglobin, ≤64 mmol/mol; C-peptide, ≥0.2 nmol/L). The electroporation dose was optimized during the study, starting with single 600 V and ending with double 750 V treatments. All patients underwent ReCET, after which insulin was discontinued and semaglutide (glucagon-like peptide-1 receptor agonist) was initiated. The primary endpoints were feasibility (procedure time [from catheter in to catheter out], technical success rate), safety, and efficacy (patients off insulin at 6 months; HbA1c, ≤58 mmol/mol).
Results
Fourteen patients underwent endoscopic ReCET. The median procedure time was 58 (interquartile range, 49-73) minutes. ReCET demonstrated a technical success rate of 100%. No device-related severe adverse events or severe hypoglycemic events were observed. At the 12-month follow-up, 12 (86%) patients remained off exogenous insulin therapy, with significant improvements in glycemic control and metabolic parameters. The 2 patients in whom insulin therapy was reintroduced both received ReCET at the lowest voltage (single 600 V).
Conclusion
These results suggest that ReCET is feasible and safe. In combination with semaglutide, ReCET may be a promising therapeutic option to replace insulin therapy in selected T2D patients while improving glycemic control and metabolic health."
Novel procedure combined with semaglutide may eliminate insulin dependency in type 2 diabetes (original news release) "Groundbreaking research presented today at UEG Week 2024 reveals a promising new treatment strategy for type 2 diabetes (T2D) that could significantly reduce or even eliminate the need for insulin therapy."
Recellularization via electroporation therapy of the duodenum combined with glucagon-like peptide 1 receptor agonist to replace insulin therapy in patients with type 2 diabetes: 12-month results of a first-in-human study (no public access; I believe this is the underlying study, both sources above to not reference any related research paper for some odd reason)
No comments:
Post a Comment